Two medicines, side by side
Abaloparatide vs aspirin
Abaloparatide is labeled for osteoporosis; aspirin for pain, cough and cold and fever. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of abaloparatide since 2017 and of aspirin since 1965.
Check it at the source: the abaloparatide FDA label on DailyMed (effective August 11, 2026); the aspirin FDA label on DailyMed (effective September 9, 2025).
Highlights of the abaloparatide record
Abaloparatide (Tymlos) · label of August 11, 2026
Used for
From the label: indicationsTYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. […]
On the market
- Earliest approval on file
- April 28, 2017
- Generic labelers
- none listed
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the aspirin record
Aspirin (Measurin) · label of September 9, 2025
Used for
From the label: indicationsTemporarily relieves headache toothache pain and fever of colds muscle pain menstrual pain minor pain of arthritis
On the market
- Earliest approval on file
- June 25, 1965
- Generic labelers
- none listed
- Pharmacy cost
- $0.0142 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 1
Source: FDA drug labels via openFDA (Abaloparatide label of August 11, 2026, Aspirin label of September 9, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do abaloparatide and aspirin differ on the record?
| Abaloparatide | Aspirin | |
|---|---|---|
| Labeled for | Osteoporosis | Pain, Cough and cold, Fever |
| Pharmacologic class | Parathyroid Hormone-Related Peptide Analog | n/a |
| How it works (label) | Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. | n/a |
| Half-life (label) | n/a | n/a |
| Earliest approval on file (Drugs@FDA) | April 28, 2017 | June 25, 1965 |
| First generic approved | none | none |
| Generic labelers (NDC) | none listed | none listed |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | n/a | $0.0142 per tablet (Aspirin ec 81 mg tablet) |
| 12-month price change | n/a | -2% |
| Boxed warning | No | No |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 0 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 29,258 | 534,208 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to abaloparatide
- every medicine labeled for the same conditions